Disclosed are .sup.13N-oxytocin molecules, methods of manufacture of .sup.13N-oxytocin molecules and methods of use of .sup.13N-oxytocin molecules in the determination of the distribution and kinetics of .sup.13N-oxytocin molecules after craniofacial or other application methods.

Disclosed are .sup.13N-oxytocin molecules, methods of manufacture of .sup.13N-oxytocin molecules and methods of use of .sup.13N-oxytocin molecules in the determination of the distribution and kinetics of .sup.13N-oxytocin molecules after craniofacial or other application methods.

An object of the present invention is to provide a simple purifying method, measuring method, and kit. The present invention is an oxytocin purifying method including treating a sample with an acid or a salt thereof, and treating the sample treated with the acid or the salt thereof with a hydrophobic carrier, and related to the purifying method, measuring method including the purifying method, and kit, in which the acid or the salt thereof is at least one or more acids or salts thereof selected from the group consisting of hydrochloric acid, acetic acid, sulfuric acid, sodium hydrogensulfate, potassium hydrogensulfate, lithium hydrogensulfate, ammonium sulfate, and a mixture thereof, and the hydrophobic carrier is a hydrophobic carrier having at least one or more functional groups on the surface, selected from the group consisting of an alkyl group having 4 to 6 carbon atoms, an alkylene glycol group, and a phenyl group.

The present invention relates to metabolically stable and non-immunogen analogs completely hydrosolubleat physiological pH, and their use for the prevention or treatment of diseases mediated by G-protein coupled receptor (GPCR), in particular (Central Nervous System) CNS and cardiovascular diseases or disorders, or their use in diagnostic methods.

The present invention relates to metabolically stable and non-immunogen analogs completely hydrosolubleat physiological pH, and their use for the prevention or treatment of diseases mediated by G-protein coupled receptor (GPCR), in particular (Central Nervous System) CNS and cardiovascular diseases or disorders, or their use in diagnostic methods.

A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.

Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.

Vasopressin-2 receptor agonists, pharmaceutical compositions thereof and methods for using the foregoing for treating diabetes insipidus, primary nocturnal enuresis, and nocturia.

An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.

An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.